Tang-Du Hospital
249
55
59
32
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
1.6%
4 terminated/withdrawn out of 249 trials
88.9%
+2.4% vs industry average
14%
35 trials in Phase 3/4
3%
1 of 32 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (249)
Laparoscopic Staging for Stage III Gastric Cancer
Role: collaborator
An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing SAP by Intravenous Pump-Delivered Propranolol in Patients With ICH
Role: lead
Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions
Role: lead
Intra-arterial Methylprednisolone After Endovascular Thrombectomy
Role: lead
Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)
Role: lead
Efficacy and Safety of Fully Resorbable Sinus Drug-eluting Stents in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps After Surgery: A Prospective, Randomized Controlled Trial
Role: lead
Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility
Role: lead
Bacteria in Atherosclerotic Plaques and Adverse Events
Role: lead
The Chinese Familial Alzheimer's Network
Role: collaborator
China Cognition and Aging Study
Role: collaborator
Optimizing Early Nutrition Support in Severe Stroke-2
Role: collaborator
Continuous HRV Monitoring for Predicting Response to Biologic Therapy in IBD
Role: collaborator
Anesthesia Comparison in Early-stage Small NSCLC: A Multicenter RCT
Role: lead
Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC
Role: lead
Intrathoracic Chemotherapy for TETs With Pleural Spread or Recurrence (CHOICE-2)
Role: collaborator
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
Role: lead
Ofatumumab in AQP4-IgG Seropositive NMOSD
Role: lead
TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study
Role: lead
Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma
Role: lead
Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)
Role: lead